Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of BeOne Medicines Ltd. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
BeOne Medicines Ltd. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • BeOne Medicines Ltd. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $149,241,000.
  • BeOne Medicines Ltd. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $416,854,000.
  • BeOne Medicines Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $416,854,000.
  • BeOne Medicines Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $533,001,000, a 35% increase from 2023.
  • BeOne Medicines Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $825,836,000, a 58% increase from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

BeOne Medicines Ltd. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $416,854,000 $149,241,000 +$234,592,000 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $182,262,000 $147,164,000 +$245,468,000 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $63,206,000 $99,549,000 +$205,469,000 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $268,675,000 $20,900,000 +$264,326,000 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $533,001,000 $85,351,000 +$265,421,000 +76% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $798,422,000 $98,304,000 -$327,642,000 -143% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $470,780,000 $105,920,000 +$261,543,000 +71% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $732,323,000 $243,426,000 +$93,513,000 +28% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $825,836,000 $350,772,000 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $229,338,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $367,463,000 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $336,939,000 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q3 2017 $34,549,000 $114,223,000 +$149,590,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2017 2017 Q3
Q2 2017 $184,139,000 $60,479,000 -$36,490,000 -152% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q1 2017 $147,649,000 $50,443,000 -$28,486,000 -130% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q4 2016 $119,163,000 $37,850,000 01 Oct 2016 31 Dec 2016 10-K 22 Mar 2017 2016 FY
Q3 2016 $35,367,000 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 $23,989,000 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $21,957,000 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1

BeOne Medicines Ltd. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $416,854,000 +$949,855,000 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $533,001,000 +$292,835,000 +35% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $825,836,000 +$1,135,201,000 +58% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $1,961,037,000 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2016 $119,163,000 -$62,061,000 -109% 01 Jan 2016 31 Dec 2016 10-K 22 Mar 2017 2016 FY
2015 $57,102,000 -$38,556,000 -208% 01 Jan 2015 31 Dec 2015 10-K 22 Mar 2017 2016 FY
2014 $18,546,000 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.